П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burde	en							

hours per respo	-
<u>.                                    </u>	

1. Nume and Address of Reporting reison			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Denali Therapeutics Inc.</u> [ DNLI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Ho Carole			<u> </u>		Director	10% Owner			
·		(1.4:-1-11-)		X	Officer (give title below)	Other (specify below)			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		Chief Medical C	Officer			
C/O DENALI T	HERAPEUTICS I	NC.	06/10/2019						
161 OYSTER PO	DINT BLVD.								
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joint/Group Filing	(Check Applicable			
SOUTH SAN	СА	94080		X	Form filed by One Repo	rting Person			
FRANCISCO					Form filed by More than Person	One Reporting			
(City)	(State)	(Zip)							

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	ecurity (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 8			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
		(Month/Day/rear)	Code V		Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)	(1) (1150.4)	(Instr. 4)
Common Stock								46,875	D <sup>(1)</sup>	
Common Stock								25,000	I	See footnote <sup>(2)</sup>
Common Stock	06/10/2019		М		711	A	\$5.28	711	D	
Common Stock	06/10/2019		S <sup>(3)</sup>		711	D	\$18.62(4)	0	D	
Common Stock	06/10/2019		М		3,906	A	\$5.28	3,906	D	
Common Stock	06/10/2019		S <sup>(3)</sup>		3,906	D	<b>\$18.81</b> <sup>(5)</sup>	0	D	
Common Stock	06/10/2019		S <sup>(3)</sup>		12,883	D	\$18.78 <sup>(6)</sup>	90,923	Ι	See footnote <sup>(7)</sup>

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$5.28	06/10/2019		М			711	(8)	07/01/2026	Common Stock	711	\$0.00	95,169	D	
Stock Option (right to buy)	\$5.28	06/10/2019		М			3,906	(9)	03/07/2027	Common Stock	3,906	\$0.00	82,033	D	

#### Explanation of Responses:

1. The shares are held of record by Carole Ho and Rajat Rohatgi.

2. The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.

3. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.

7. The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

8. Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter.

9. Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.

**Remarks:** 

<sup>4.</sup> The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$18.60 to \$18.67 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

<sup>5.</sup> The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$18.55 to \$19.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

<sup>6.</sup> The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$18.49 to \$19.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

<u>/s/ Tyler Nielsen, by power of</u> <u>06/12/2019</u>

<u>attorney</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.